DexCom, Inc. DXCM
86.62
(0.85)
(0.97%)
as of 25 Sep
- Market cap
- $33.0B
- P/E
- 33.4×
Follow DXCM
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
DexCom, Inc. (DXCM) Return on assets
DexCom, Inc.'s return on assets over the twelve months to 30 June 2026 was 14.5%, up 1.5 percentage points from fiscal 2025 (13.0%). Over the past ten years it has ranged from −24.2% (fiscal 2015) to 16.4% (fiscal 2020); the current reading is higher than 91% of that period. That is above the Medical Devices industry median of −19.7% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Annual
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 13.0% | 4.00 |
| FY2024 | 9.04% | (0.25) |
| FY2023 | 9.29% | 2.68 |
| FY2022 | 6.61% | 1.91 |
| FY2021 | 4.70% | (11.74) |
| FY2020 | 16.4% | 11.75 |
| FY2019 | 4.69% | 13.70 |
| FY2018 | −9.01% | (1.33) |
| FY2017 | −7.68% | 11.20 |
| FY2016 | −18.9% | 5.29 |
Against its own ten years
Low −24.2%
High 16.4%
Ten-year median
4.70%
Current reading's percentile
91
Return on assets against peers
| Company | Return on assets |
|---|---|
| DXCM DexCom, Inc. | 14.5% |
| PEN Penumbra, Inc. compare | 8.80% |
| BSX Boston Scientific Corporation compare | 8.47% |
| STE STERIS plc compare | 7.62% |
| EW Edwards Lifesciences Corporation compare | 7.35% |
| GEHC GE HealthCare Technologies Inc. compare | 5.45% |
| PHG Koninklijke Philips N.V. compare | 4.21% |
| ZBH Zimmer Biomet Holdings, Inc. compare | 3.53% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| Medical Devices industry median | −19.7% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on DXCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement